Adebelizumab Combined With Chemotherapy and Radiotherapy Treat ES-SCLC
ConditionExtensive Small Cell Lung Cancer
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorQianfoshan Hospital
About this trial
To observe the efficacy and safety of adebelizumab combined with chemotherapy and sequential adebelizumab combined with radiotherapy in the treatment of newly diagnosed extensive small cell lung cancer.
Eligibility criteria
Qualifiers
Age 18-75 years old, both male and female;
Extensive small cell lung cancer (metastatic lesions ≤3 organs, ≤5 lesions) confirmed by histology or cytology (according to the Veterans Administration Lung Study Group (VALG staging), including asymptomatic brain metastasis, multiple lung metastases, supraclavicular or mediastinal lymph node metastasis, bone metastasis, adrenal metastasis, retroperitoneal lymph node metastasis, etc.;
The score of ECOG physical condition is 0~1;
Never received first-line systemic therapy for ES-SCLC or immune checkpoint inhibitors before;
Disqualifiers
Symptomatic brain metastasis and liver metastasis;
The effusion in the third space with clinical symptoms needs repeated drainage, such as pericardial effusion, pleural effusion and peritoneal effusion that cannot be controlled by pumping or other treatments;
Uncontrollable or symptomatic hypercalcemia;
Other malignant tumors occurred less than 5 years before the first dose, except for cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical surgery and ductal carcinoma in situ after radical surgery (hormone therapy for non-metastatic prostate cancer or breast cancer is allowed);
Trial design
Treatments tested in this trial
- Adebelizumab+Carboplatin+Etoposide+Concurrent Radiotherapy
Treatment groups
51 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov